^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CD5 CAR T (CT125B)

    i
    Other names: CD5 CAR T (CT125B), donor derived CD5 CAR T (CT125B) cells
    Associations

    News

    Trials
    Company:
    Beijing Boren Hospital
    Drug class:
    CD5-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    1year
    Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma (clinicaltrials.gov)
    P1, N=0, Withdrawn, Beijing Boren Hospital | N=18 --> 0 | Trial completion date: Jul 2024 --> Dec 2023 | Recruiting --> Withdrawn | Trial primary completion date: Jul 2024 --> Dec 2023
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    CD5 (CD5 Molecule)
    |
    CD5 positive
    |
    cyclophosphamide • CD5 CAR T (CT125B)
    over3years
    Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma (clinicaltrials.gov)
    P1, N=18, Recruiting, Beijing Boren Hospital
    New P1 trial
    |
    CD5 (CD5 Molecule)
    |
    CD5 positive
    |
    cyclophosphamide • CD5 CAR T (CT125B)